胃部・食道胃接合部腺癌市場:現在・未来プレイヤー

◆英語タイトル:Gastric and Gastroesophageal Junction Adenocarcinoma - Current and Future Players
◆商品コード:GDHC1047FPR
◆発行会社(調査会社):GlobalData
◆発行日:2015年12月9日
◆ページ数:122
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,995 ⇒換算¥332,445見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,990 ⇒換算¥664,890見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD8,985 ⇒換算¥997,335見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Gastric and Gastroesophageal Junction Adenocarcinoma – Current and Future Players
Summary

GlobalData has released its pharma report, “Gastric and Gastroesophageal Junction Adenocarcinoma – Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJAC) Market. The report identifies and analyses the key companies shaping and driving the global G/GEJAC market. The report provides insight into the competitive G/GEJAC landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Investigation of current and future market competition for G/GEJAC
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of G/GEJAC sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving G/GEJAC market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global G/GEJAC market landscape? Identify, understand and capitalize

【レポートの目次】

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Market Outlook
3.1 Global Markets
3.1.1 Forecast
3.1.2 Drivers and Barriers – Global Issues
4 Current and Future Players
4.1 Overview
4.2 Trends in Corporate Strategy
4.3 Company Profiles
4.3.1 Bristol-Myers Squibb
4.3.2 Eli Lilly and Company
4.3.3 Merck & Co.
4.3.4 Roche
4.3.5 Taiho Pharmaceutical
4.3.6 Sumitomo Dainippon Pharma
5 Appendix
5.1 Bibliography
5.2 Abbreviations
5.3 Methodology
5.4 Forecasting Methodology
5.4.1 Hospitalized MRSA Patients
5.4.2 Percentage of Drug-Treated MRSA Patients
5.4.3 Drugs Included in Each Therapeutic Class
5.4.4 Launch, Label Expansion, and Patent Expiry Dates
5.4.5 General Pricing Assumptions
5.4.6 Individual Drug Assumptions
5.4.7 Generic Erosion
5.4.8 Pricing of Pipeline Agents
5.5 Primary Research – KOLs Interviewed for This Report
5.6 Primary Research – Prescriber Survey
5.7 About the Authors
5.7.1 Author and Therapy Area Director
5.7.2 Author
5.7.3 Epidemiologist
5.7.4 Global Director of Therapy Analysis and Epidemiology
5.7.5 Global Head of Healthcare
5.8 About GlobalData
5.9 Disclaimer

1.1 List of Tables
Table 1: Global Sales Forecast ($m) for G/GEJAC, 2014-2024
Table 2: G/GEJAC Market - Drivers and Barriers, 2015
Table 3: Key Companies in the G/GEJAC Market in the 8MM, 2014-2024
Table 4: BMS’ G/GEJAC Portfolio Assessment, 2015
Table 5: Eli Lilly’s G/GEJAC Portfolio Assessment, 2015
Table 6: Merck & Co.’s G/GEJAC Portfolio Assessment, 2015
Table 7: Roche’s G/GEJAC Portfolio Assessment, 2015
Table 8: Taiho’s G/GEJAC Portfolio Assessment, 2015
Table 9: SDP’s G/GEJAC Portfolio Assessment, 2015
Table 10: Key Historical and Projected Launch Dates for MRSA Across the 7MM
Table 11: Key Historical and Projected Label Expansion Dates for MRSA Across the 7MM
Table 12: Key Historical and Projected Patent Expiry Dates for MRSA Across the 7MM
Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Global Sales for G/GEJAC by Region, 2014-2024
Figure 2: Global Sales of Branded Products for G/GEJAC by Company, 2014-2024
Figure 3: Company Portfolio Gap Analysis in G/GEJAC, 2014-2024
Figure 4: Bristol-Myers Squibb SWOT Analysis in G/GEJAC, 2014-2024
Figure 5: Eli Lilly SWOT Analysis in G/GEJAC, 2014-2024
Figure 6: Roche SWOT Analysis in G/GEJAC, 2014-2024
Figure 7: Taiho SWOT Analysis in G/GEJAC, 2014-2024
Figure 8: Sumitomo Dainippon SWOT Analysis in G/GEJAC, 2014-2024

【掲載企業】

Bristol-Myers Squibb
Eli Lilly and Company
Merck & Co.
Roche
Taiho Pharmaceutical
Sumitomo Dainippon Pharma

★調査レポート[胃部・食道胃接合部腺癌市場:現在・未来プレイヤー]販売に関する免責事項
★調査レポート[胃部・食道胃接合部腺癌市場:現在・未来プレイヤー]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆